Dateline City:
PHILADELPHIA
Data Formed the Basis for KEYTRUDA U.S. FDA Submission and Breakthrough Therapy Designation in Advanced NSCLC
PHILADELPHIA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced new data from KEYNOTE-001, a Phase 1b study evaluating
KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy,
in nave and previously-treated patients with advanced non-small cell
lung cancer (NSCLC).
Language:
English
Contact:
Media:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more